February 26th, 2013
Episode 156 of 333 episodes
Dr Mark Porter puts the Pharmaceutical Industry in the spotlight as some clinical trials are criticised for testing new drugs against a much weaker rival so that the results appear much better than they really are. Kamran Abbasi and Dr Bina Rawal from the Association of British Pharmaceutical Industry discuss if the hurdles are being set too low, so that a new therapy comes out on top. And what if sustained periods of adversity in childhood are associated with permanent structural changes in brain development? So suggests new research into adolescents with Conduct Disorder - a controversial diagnosis given to 1 in 20 teenagers in the UK with aggressive or anti-social behaviour. Mark Porter investigates.